In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 24, 2020
Industry-Led Manufacturing Group Welcomes UK Government Investment
Author(s)BioPharm International Editors
A UK BioIndustry Association industry-led vaccine manufacturing group has welcomed a recent announcement by the government of the UK, that it will receive £14 million (US$17.3 million) in investment to rapidly scale up the development of vaccines for COVID-19.
Advertisement
A UK BioIndustry Association (BIA) industry-led vaccine manufacturing group has welcomed a recent announcement by the government of the United Kingdom, that it will receive £14 million (US$17.3 million) in investment to rapidly scale up the development of vaccines for COVID-19.
According to an April 17, 2020 press release, the group will work closely with the UK government and will report directly into the chief scientific advisor, Sir Patrick Vallance, on the progress of treatments and vaccines. Founded by BIA, the group will consider any vaccines or therapies for COVID-19, irrespective of where they are based, and will help where possible.
The group is a collaboration of private and public-sector companies, as well as academia and universities, and is chaired by Ian McCubbin, OBE, the former vice-president for Global Manufacturing and Supply at GlaxoSmithKline. Current work being supported by the group includes an adenovirus vaccine candidate from the Jenner Institute at the University of Oxford, and an mRNA vaccine currently being worked on at the Imperial College London.
“[This] announcement will help accelerate the manufacturing capacity and capability of the UK and support vaccine candidates and other COVID-19 therapies, which are needed in this global health crisis,” said Steve Bates OBE, CEO of the BIA, in the press release. “The industry-led vaccine manufacturing group has been working closely with Oxford University and Imperial College London, to assess supply chains and understand what they require to scale and rapidly deploy their vaccines. The UK has world leading science in academia, vaccines, and advanced therapies, and with the government’s announcement, we can begin to create the capability to industrialise for health and economic benefits now, and in the future. BIA is proud to have established this industry-led vaccine manufacturing group, drawing on expertise from across the UK life sciences ecosystem and under the excellent leadership of Ian McCubbin, this project is now an important part of the jigsaw in tackling COVID-19.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5